SU1597101A3 - Способ получени производных замещенного бензамида или их фармацевтически приемлемых кислотно-аддитивных солей - Google Patents
Способ получени производных замещенного бензамида или их фармацевтически приемлемых кислотно-аддитивных солей Download PDFInfo
- Publication number
- SU1597101A3 SU1597101A3 SU874202484A SU4202484A SU1597101A3 SU 1597101 A3 SU1597101 A3 SU 1597101A3 SU 874202484 A SU874202484 A SU 874202484A SU 4202484 A SU4202484 A SU 4202484A SU 1597101 A3 SU1597101 A3 SU 1597101A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- ethyl alcohol
- alcohol
- ethyl
- chloro
- amino
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract 7
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title claims description 5
- 150000003936 benzamides Chemical class 0.000 title claims description 4
- 238000000034 method Methods 0.000 title abstract description 4
- 239000000654 additive Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 54
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 239000002253 acid Substances 0.000 claims abstract description 6
- 230000002708 enhancing effect Effects 0.000 claims abstract 2
- 230000005176 gastrointestinal motility Effects 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 147
- 235000019441 ethanol Nutrition 0.000 claims description 72
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 53
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 26
- -1 4-benzyl-2-morpholinyl Chemical group 0.000 claims description 24
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 17
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 239000012458 free base Substances 0.000 claims description 14
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 12
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 239000011541 reaction mixture Substances 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 7
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 210000002784 stomach Anatomy 0.000 claims description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- XWGYOMHQGQZRLC-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxybenzoic acid Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(O)=O XWGYOMHQGQZRLC-UHFFFAOYSA-N 0.000 claims description 3
- RVEATKYEARPWRE-UHFFFAOYSA-N 4-amino-5-chloro-2-methoxybenzoic acid Chemical compound COC1=CC(N)=C(Cl)C=C1C(O)=O RVEATKYEARPWRE-UHFFFAOYSA-N 0.000 claims description 3
- 239000001530 fumaric acid Substances 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- 230000004899 motility Effects 0.000 claims description 3
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 claims description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 2
- ODYRBQWYNNOGQN-UHFFFAOYSA-N 4-[[2-(aminomethyl)morpholin-4-yl]methyl]benzonitrile Chemical compound C1COC(CN)CN1CC1=CC=C(C#N)C=C1 ODYRBQWYNNOGQN-UHFFFAOYSA-N 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004106 citric acid Drugs 0.000 claims description 2
- 229960002303 citric acid monohydrate Drugs 0.000 claims description 2
- 238000001953 recrystallisation Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229960004756 ethanol Drugs 0.000 claims 50
- 230000000694 effects Effects 0.000 claims 13
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 5
- 210000003169 central nervous system Anatomy 0.000 claims 5
- 239000000460 chlorine Substances 0.000 claims 5
- 229910052801 chlorine Inorganic materials 0.000 claims 5
- 230000002496 gastric effect Effects 0.000 claims 4
- 230000030136 gastric emptying Effects 0.000 claims 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims 3
- 206010047700 Vomiting Diseases 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 150000002431 hydrogen Chemical group 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims 3
- 238000005303 weighing Methods 0.000 claims 3
- ZWNMRNMIZKFLBZ-UHFFFAOYSA-N 2-(4-benzylmorpholin-2-yl)ethanamine Chemical compound C1COC(CCN)CN1CC1=CC=CC=C1 ZWNMRNMIZKFLBZ-UHFFFAOYSA-N 0.000 claims 2
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- KZKOWXZFTMYRSE-UHFFFAOYSA-N 5-chloro-4-(dimethylamino)-2-methoxybenzoic acid Chemical compound COC1=CC(N(C)C)=C(Cl)C=C1C(O)=O KZKOWXZFTMYRSE-UHFFFAOYSA-N 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- 208000007882 Gastritis Diseases 0.000 claims 2
- 241000699670 Mus sp. Species 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 239000011737 fluorine Chemical group 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 claims 2
- RPOGJJLTBMSAKR-UHFFFAOYSA-N methyl 4-acetamido-5-chloro-2-ethoxybenzoate Chemical compound CCOC1=CC(NC(C)=O)=C(Cl)C=C1C(=O)OC RPOGJJLTBMSAKR-UHFFFAOYSA-N 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 2
- 239000007858 starting material Substances 0.000 claims 2
- CKZVBXBEDDAEFE-UHFFFAOYSA-N (4-benzylmorpholin-2-yl)methanamine Chemical compound C1COC(CN)CN1CC1=CC=CC=C1 CKZVBXBEDDAEFE-UHFFFAOYSA-N 0.000 claims 1
- HAFWELDDNUXLCK-TYYBGVCCSA-N (e)-but-2-enedioic acid;hydrate Chemical compound O.OC(=O)\C=C\C(O)=O HAFWELDDNUXLCK-TYYBGVCCSA-N 0.000 claims 1
- DBUAYOWCIUQXQW-UHFFFAOYSA-N 1,3-benzodioxole-4-carboxylic acid Chemical compound OC(=O)C1=CC=CC2=C1OCO2 DBUAYOWCIUQXQW-UHFFFAOYSA-N 0.000 claims 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 claims 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims 1
- LRZSAGKIMYFLHY-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;dihydrate Chemical compound O.O.OC(=O)CC(O)(C(O)=O)CC(O)=O LRZSAGKIMYFLHY-UHFFFAOYSA-N 0.000 claims 1
- QWYPXBYEAOOUNJ-UHFFFAOYSA-N 4-[[2-(2-aminoethyl)morpholin-4-yl]methyl]benzonitrile Chemical compound C1COC(CCN)CN1CC1=CC=C(C#N)C=C1 QWYPXBYEAOOUNJ-UHFFFAOYSA-N 0.000 claims 1
- ICNWZXFWTBMBKT-UHFFFAOYSA-N 4-acetamido-5-chloro-2-ethoxybenzoic acid Chemical compound CCOC1=CC(NC(C)=O)=C(Cl)C=C1C(O)=O ICNWZXFWTBMBKT-UHFFFAOYSA-N 0.000 claims 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 1
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 claims 1
- 241000416162 Astragalus gummifer Species 0.000 claims 1
- QNAATQMGWNUOPK-UHFFFAOYSA-N C1COCC(N1CC2=CC=C(C=C2)F)CCN Chemical compound C1COCC(N1CC2=CC=C(C=C2)F)CCN QNAATQMGWNUOPK-UHFFFAOYSA-N 0.000 claims 1
- OMPIYDSYGYKWSG-UHFFFAOYSA-N Citronensaeure-alpha-aethylester Natural products CCOC(=O)CC(O)(C(O)=O)CC(O)=O OMPIYDSYGYKWSG-UHFFFAOYSA-N 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 206010018045 Gastroptosis Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029333 Neurosis Diseases 0.000 claims 1
- 241000700157 Rattus norvegicus Species 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 229920001615 Tragacanth Polymers 0.000 claims 1
- HSPSHZXMUKHKPV-UHFFFAOYSA-N [4-[(2-chlorophenyl)methyl]-6-methylmorpholin-2-yl]methanamine Chemical compound C1C(CN)OC(C)CN1CC1=CC=CC=C1Cl HSPSHZXMUKHKPV-UHFFFAOYSA-N 0.000 claims 1
- 206010000059 abdominal discomfort Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000007059 acute toxicity Effects 0.000 claims 1
- 231100000403 acute toxicity Toxicity 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- CSTBBLHIGMTEAZ-UHFFFAOYSA-N chloroform;ethyl acetate;hexane Chemical compound ClC(Cl)Cl.CCCCCC.CCOC(C)=O CSTBBLHIGMTEAZ-UHFFFAOYSA-N 0.000 claims 1
- 208000023652 chronic gastritis Diseases 0.000 claims 1
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 claims 1
- 208000027744 congestion Diseases 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 claims 1
- 125000006317 cyclopropyl amino group Chemical group 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000001627 detrimental effect Effects 0.000 claims 1
- LJSQFQKUNVCTIA-UHFFFAOYSA-N diethyl sulfide Chemical compound CCSCC LJSQFQKUNVCTIA-UHFFFAOYSA-N 0.000 claims 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- 229940057975 ethyl citrate Drugs 0.000 claims 1
- 238000002474 experimental method Methods 0.000 claims 1
- 210000000744 eyelid Anatomy 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 239000010200 folin Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- QKGYJVXSKCDGOK-UHFFFAOYSA-N hexane;propan-2-ol Chemical compound CC(C)O.CCCCCC QKGYJVXSKCDGOK-UHFFFAOYSA-N 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 231100000053 low toxicity Toxicity 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- NMGBXFJAUQDKNO-UHFFFAOYSA-N methyl 4-amino-5-chloro-2-ethoxybenzoate Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)OC NMGBXFJAUQDKNO-UHFFFAOYSA-N 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 229960004503 metoclopramide Drugs 0.000 claims 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims 1
- KJBLQGHJOCAOJP-UHFFFAOYSA-N metoclopramide hydrochloride Chemical compound O.Cl.CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC KJBLQGHJOCAOJP-UHFFFAOYSA-N 0.000 claims 1
- 230000007659 motor function Effects 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 208000015238 neurotic disease Diseases 0.000 claims 1
- 239000012044 organic layer Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000005544 phthalimido group Chemical group 0.000 claims 1
- 230000035790 physiological processes and functions Effects 0.000 claims 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- SAALQYKUFCIMHR-UHFFFAOYSA-N propan-2-ol;2-propan-2-yloxypropane Chemical compound CC(C)O.CC(C)OC(C)C SAALQYKUFCIMHR-UHFFFAOYSA-N 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 239000012258 stirred mixture Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 238000011287 therapeutic dose Methods 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 239000000196 tragacanth Substances 0.000 claims 1
- 229940116362 tragacanth Drugs 0.000 claims 1
- 235000010487 tragacanth Nutrition 0.000 claims 1
- 235000013769 triethyl citrate Nutrition 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 abstract 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- XXUNIGZDNWWYED-UHFFFAOYSA-N 2-methylbenzamide Chemical compound CC1=CC=CC=C1C(N)=O XXUNIGZDNWWYED-UHFFFAOYSA-N 0.000 description 2
- JHSPPBBJOLKJDH-UHFFFAOYSA-N [4-[(4-fluorophenyl)methyl]morpholin-2-yl]methanamine Chemical compound C1COC(CN)CN1CC1=CC=C(F)C=C1 JHSPPBBJOLKJDH-UHFFFAOYSA-N 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- VDVJGIYXDVPQLP-UHFFFAOYSA-N piperonylic acid Chemical compound OC(=O)C1=CC=C2OCOC2=C1 VDVJGIYXDVPQLP-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- FDAXHDFKDZSHQV-UHFFFAOYSA-N 3-(4-benzylmorpholin-2-yl)propan-1-amine Chemical compound C1COC(CCCN)CN1CC1=CC=CC=C1 FDAXHDFKDZSHQV-UHFFFAOYSA-N 0.000 description 1
- ABFYEILPZWAIBN-UHFFFAOYSA-N 3-(iminomethylideneamino)-n,n-dimethylpropan-1-amine;hydrochloride Chemical compound Cl.CN(C)CCCN=C=N ABFYEILPZWAIBN-UHFFFAOYSA-N 0.000 description 1
- DYBPANJQVAJWGO-UHFFFAOYSA-N CCCl.CN(C)CCCN=C=N Chemical compound CCCl.CN(C)CCCN=C=N DYBPANJQVAJWGO-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001139947 Mida Species 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- ZQZNIVUZKAVQAL-UHFFFAOYSA-N ethyl 2-(aminomethyl)morpholine-4-carboxylate Chemical compound CCOC(=O)N1CCOC(CN)C1 ZQZNIVUZKAVQAL-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- RLXDCJUIXHSXQD-UHFFFAOYSA-N oxalic acid;hydrate Chemical compound O.OC(=O)C(O)=O.OC(=O)C(O)=O RLXDCJUIXHSXQD-UHFFFAOYSA-N 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10155286 | 1986-04-30 | ||
| JP31509086 | 1986-12-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1597101A3 true SU1597101A3 (ru) | 1990-09-30 |
Family
ID=26442419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU874202484A SU1597101A3 (ru) | 1986-04-30 | 1987-04-29 | Способ получени производных замещенного бензамида или их фармацевтически приемлемых кислотно-аддитивных солей |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US4870074A (enExample) |
| EP (1) | EP0243959B1 (enExample) |
| KR (1) | KR870010030A (enExample) |
| AR (1) | AR242953A1 (enExample) |
| AU (1) | AU592177B2 (enExample) |
| CA (1) | CA1291135C (enExample) |
| CZ (1) | CZ284687B6 (enExample) |
| DE (1) | DE3781195T2 (enExample) |
| DK (1) | DK175281B1 (enExample) |
| ES (1) | ES2043617T3 (enExample) |
| FI (1) | FI87776C (enExample) |
| GR (1) | GR3005934T3 (enExample) |
| HK (1) | HK18194A (enExample) |
| HU (1) | HU198193B (enExample) |
| NZ (1) | NZ220120A (enExample) |
| PH (1) | PH24049A (enExample) |
| SK (1) | SK289787A3 (enExample) |
| SU (1) | SU1597101A3 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2257206C2 (ru) * | 1999-08-16 | 2005-07-27 | Шеринг Акциенгезелльшафт | Фармацевтическое средство, содержащее производное бензамида в качестве активного ингредиента |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2640139A1 (fr) * | 1988-12-14 | 1990-06-15 | Delagrange Laboratoires | Application de benzamides substitues comme gastromoteurs |
| US5395832A (en) * | 1991-02-15 | 1995-03-07 | Hokuriku Seiyaku Co., Ltd. | Benzamide derivatives |
| TW243449B (enExample) * | 1991-02-15 | 1995-03-21 | Hokuriku Pharmaceutical | |
| KR970702247A (ko) * | 1994-03-30 | 1997-05-13 | 고야 마사시 | 벤조산 화합물 및 이들의 약제로서의 용도(benzoic acid compound and use thereof as medicine) |
| US5864039A (en) * | 1994-03-30 | 1999-01-26 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzoic acid compounds and use thereof as medicaments |
| JPH11505815A (ja) * | 1995-05-23 | 1999-05-25 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | （２−モルホリニルメチル）ベンズアミン誘導体 |
| AR035205A1 (es) * | 2000-09-29 | 2004-05-05 | Glaxo Group Ltd | Compuestos utiles en el tratamiento de enfermedades inflamatorias, proceso para su preparacion, intermediarios y composiciones farmaceuticas |
| EP1353918B1 (en) * | 2000-11-28 | 2005-01-12 | Smithkline Beecham Plc | Morpholine derivatives as antagonists of orexin receptors |
| JP4829417B2 (ja) * | 2001-03-26 | 2011-12-07 | 明夫 乾 | インスリン抵抗性改善薬 |
| HUP0402611A2 (hu) * | 2001-10-08 | 2005-07-28 | Sun Pharmaceutical Industries Limited | Görcsoldó hatóanyag szakaszos leadására szolgáló rendszer |
| GB0207447D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| GB0207449D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| GB0208158D0 (en) * | 2002-03-28 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| HUP0201980A3 (en) * | 2002-06-13 | 2008-06-30 | Richter Gedeon Nyrt | Process for preparing a benzamide derivative and intermediates thereof |
| KR20060126688A (ko) * | 2003-12-09 | 2006-12-08 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 약물-함유 입자 및 그 입자를 함유하는 고형 제제 |
| US8524736B2 (en) | 2004-01-07 | 2013-09-03 | Armetheon, Inc. | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| US8138204B2 (en) * | 2004-01-07 | 2012-03-20 | Aryx Therapeutics, Inc. | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| CA2551686C (en) | 2004-01-07 | 2014-09-23 | Ian Irwin | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| CA2579207C (en) | 2004-09-08 | 2011-10-18 | Mitsubishi Pharma Corporation | Morpholine compound |
| EP1904481B1 (en) | 2005-06-23 | 2016-02-17 | Array Biopharma, Inc. | Process for preparing benzimidazole compounds |
| EP1919909B1 (en) * | 2005-08-31 | 2013-08-21 | Armetheon, Inc. | Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders |
| CA2633042A1 (en) * | 2005-12-20 | 2007-07-05 | Merck & Co., Inc. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| KR100750593B1 (ko) * | 2006-03-16 | 2007-08-20 | 동우신테크 주식회사 | 치환된 벤즈아미드 유도체의 제조방법 |
| WO2007149929A1 (en) * | 2006-06-23 | 2007-12-27 | Aryx Therapeutics, Inc. | Piperidine derivatives for the treatment of gastrointestinal and cns disorders |
| US7528131B2 (en) | 2007-04-19 | 2009-05-05 | Concert Pharmaceuticals Inc. | Substituted morpholinyl compounds |
| CN101402633A (zh) * | 2007-09-11 | 2009-04-08 | 上海恒瑞医药有限公司 | 苯甲酰胺类衍生物、其制备方法及其在医药上的用途 |
| US20110053942A1 (en) | 2008-02-13 | 2011-03-03 | Dainippon Sumitomo Pharma Co., Ltd. | Orally disintegrating tablets |
| TWI423967B (zh) * | 2008-02-21 | 2014-01-21 | Dainippon Sumitomo Pharma Co | 醯胺衍生物及含有其之醫藥組合物 |
| CN102548542B (zh) | 2009-08-11 | 2013-11-20 | 大日本住友制药株式会社 | 含有两种以上粒子的口腔速崩片 |
| WO2011107903A1 (en) | 2010-03-04 | 2011-09-09 | Ranbaxy Laboratories Limited | Highly pure mosapride citrate dihydrate and processes for its preparation |
| ES2587304T3 (es) | 2011-02-25 | 2016-10-21 | Yuhan Corporation | Derivados de diaminopirimidina y procedimientos para la preparación de los mismos |
| KR101657616B1 (ko) | 2013-05-24 | 2016-09-19 | 주식회사유한양행 | 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| CN111349052B (zh) * | 2020-04-07 | 2021-02-12 | 福建海西新药创制有限公司 | 一种枸橼酸莫沙必利的合成方法 |
| CN114560822B (zh) * | 2020-11-27 | 2024-05-28 | 鲁南制药集团股份有限公司 | 一种莫沙必利的二羧酸晶体 |
| CN114591260B (zh) * | 2020-12-05 | 2025-07-11 | 鲁南制药集团股份有限公司 | 一种莫沙必利有机酸盐 |
| CN119241464A (zh) * | 2024-10-22 | 2025-01-03 | 吉林修正药业新药开发有限公司 | 一种枸橼酸莫沙必利杂质化合物及其制备方法 |
| CN119241463A (zh) * | 2024-10-22 | 2025-01-03 | 吉林修正药业新药开发有限公司 | 一种枸橼酸莫沙必利杂质化合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH451142A (de) * | 1965-01-19 | 1968-05-15 | Sandoz Ag | Verfahren zur Herstellung neuer basisch substituierter Benzoesäureamide |
| US4029786A (en) * | 1972-08-11 | 1977-06-14 | Imperial Chemical Industries Limited | Morpholine derivatives for treating depression |
| US4323503A (en) * | 1976-08-04 | 1982-04-06 | Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France | Substituted 2,3-alkylene di (oxy) benzamides and derivatives |
| US4210754A (en) * | 1977-02-01 | 1980-07-01 | Hoffmann-La Roche Inc. | Morpholino containing benzamides |
| US4692445A (en) * | 1983-04-29 | 1987-09-08 | Rorer Pharmaceutical Corporation | Bicyclic benzenoid aminoalkylene ethers and thioethers, pharmaceutical compositions and use |
| FR2575158B1 (fr) * | 1984-12-20 | 1987-10-02 | Pf Medicament | Arylalcoyloxymethyl-2 morpholines, leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central |
| JPH0390274A (ja) * | 1989-08-28 | 1991-04-16 | Furukawa Alum Co Ltd | Ａｌ又はＡｌ合金の気相ろう付法 |
-
1987
- 1987-04-24 CZ CS872897A patent/CZ284687B6/cs not_active IP Right Cessation
- 1987-04-24 SK SK2897-87A patent/SK289787A3/sk unknown
- 1987-04-24 US US07/042,474 patent/US4870074A/en not_active Expired - Lifetime
- 1987-04-27 FI FI871828A patent/FI87776C/fi not_active IP Right Cessation
- 1987-04-28 NZ NZ220120A patent/NZ220120A/xx unknown
- 1987-04-28 CA CA000535794A patent/CA1291135C/en not_active Expired - Lifetime
- 1987-04-29 DK DK198702187A patent/DK175281B1/da not_active IP Right Cessation
- 1987-04-29 HU HU871946A patent/HU198193B/hu unknown
- 1987-04-29 EP EP87106266A patent/EP0243959B1/en not_active Expired - Lifetime
- 1987-04-29 SU SU874202484A patent/SU1597101A3/ru active
- 1987-04-29 ES ES87106266T patent/ES2043617T3/es not_active Expired - Lifetime
- 1987-04-29 PH PH35203A patent/PH24049A/en unknown
- 1987-04-29 DE DE8787106266T patent/DE3781195T2/de not_active Expired - Lifetime
- 1987-04-30 AR AR87307449A patent/AR242953A1/es active
- 1987-04-30 AU AU72275/87A patent/AU592177B2/en not_active Expired
- 1987-04-30 KR KR870004220A patent/KR870010030A/ko not_active Withdrawn
-
1992
- 1992-10-12 GR GR920402254T patent/GR3005934T3/el unknown
-
1994
- 1994-03-03 HK HK181/94A patent/HK18194A/en not_active IP Right Cessation
Non-Patent Citations (1)
| Title |
|---|
| Патент US № 4273778, КП-. А24/265, опублико 1981оПатент Вел1-!кобритании № 2037740, кл, С 07 D 207/14, опублик^ 1980. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2257206C2 (ru) * | 1999-08-16 | 2005-07-27 | Шеринг Акциенгезелльшафт | Фармацевтическое средство, содержащее производное бензамида в качестве активного ингредиента |
Also Published As
| Publication number | Publication date |
|---|---|
| SK279058B6 (sk) | 1998-06-03 |
| HK18194A (en) | 1994-03-11 |
| EP0243959B1 (en) | 1992-08-19 |
| CZ289787A3 (cs) | 1998-11-11 |
| EP0243959A1 (en) | 1987-11-04 |
| DK218787D0 (da) | 1987-04-29 |
| FI871828A7 (fi) | 1987-10-31 |
| AU592177B2 (en) | 1990-01-04 |
| FI87776B (fi) | 1992-11-13 |
| GR3005934T3 (enExample) | 1993-06-07 |
| HU198193B (en) | 1989-08-28 |
| US4870074A (en) | 1989-09-26 |
| PH24049A (en) | 1990-03-05 |
| DK218787A (da) | 1987-10-31 |
| NZ220120A (en) | 1989-06-28 |
| HUT45514A (en) | 1988-07-28 |
| ES2043617T3 (es) | 1994-01-01 |
| SK289787A3 (en) | 1998-06-03 |
| DE3781195T2 (de) | 1993-02-18 |
| FI87776C (fi) | 1993-02-25 |
| DE3781195D1 (de) | 1992-09-24 |
| FI871828A0 (fi) | 1987-04-27 |
| KR870010030A (ko) | 1987-11-30 |
| AU7227587A (en) | 1987-11-05 |
| CA1291135C (en) | 1991-10-22 |
| DK175281B1 (da) | 2004-08-09 |
| CZ284687B6 (cs) | 1999-02-17 |
| AR242953A1 (es) | 1993-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4065584A (en) | Sulphur containing arylamine derivatives | |
| DK175281B1 (da) | Benzamidderivater, en fremgangsmåde til deres fremstilling samt farmaceutisk præparat indeholdende dem | |
| EP0089167B1 (en) | Dihydropyridine anti-ischaemic and antihypertensive agents, processes for their production, and pharmaceutical compositions containing them | |
| SU1417796A3 (ru) | Способ получени простых пиридин-2-эфиров или пиридин-2-тиоэфиров, или их кислотно-аддитивных солей, или пиридин-N-оксидов (его варианты) | |
| SU1375127A3 (ru) | Способ получени производных 1,2-диаминоциклобутен-3,4-диона или их хлоргидратов | |
| US4808624A (en) | Pharmacologically active substituted benzamides | |
| US4820715A (en) | Anti-emetic quinuclidinyl benzamides | |
| NZ206614A (en) | Dihydropyridine derivatives and pharmaceutical compositions | |
| US4207327A (en) | N-(4-Pyrazolidinyl)benzamides and their amino precursors | |
| SK287606B6 (sk) | Derivát pyridín-1-oxidu, jeho použitie a spôsob jeho transformácie na farmaceuticky účinné zlúčeniny | |
| SK45096A3 (en) | Alkoxy alkyl carbamates from imidazo (1,2-a)pyridines, preparation method thereof, pharmaceutical composition containing them and their use | |
| SU1301312A3 (ru) | Способ получени пиридиловых или фениловых соединений | |
| US4091100A (en) | Sulfide compounds | |
| US4056632A (en) | 2-Hydroxymethyl-2'-aminomethyl-diphenylsulfides and method of use | |
| US4301159A (en) | N-(Diethylaminoethyl)-2-alkoxy-benzamide derivatives | |
| JP4113602B2 (ja) | ピロリジン誘導体及び抗潰瘍剤、抗菌剤 | |
| US4434175A (en) | Nonsteroidal compounds as anti-inflammatory and analgesic agents | |
| US5354864A (en) | 3-(9-acridinylamino)-5-hydroxymethylaniline derivatives as anticancer agents | |
| JPS62289582A (ja) | 置換チアシクロアルケノ〔３，２−ｂ〕ピリジン類 | |
| FI96024B (fi) | Menetelmä terapeuttisesti käyttökelpoisten 3-fenyyliglutarimidijohdannaisten valmistamiseksi | |
| EP0072013B1 (en) | Pyrrole compounds as anti-inflammatory and analgesic agents | |
| US4734411A (en) | Pyrrolizidine compounds, salts thereof, process for the preparation of same and pharmaceutical agents comprising same | |
| US3954981A (en) | Triazolocycloalkylhydrothiadiazine derivatives | |
| SU1438611A3 (ru) | Способ получени производных 1,5-бензоксатиепина или его кислотно-аддитивных солей | |
| US4132796A (en) | Antipsychotic 3-trifluoromethylsulfinyl analogs of cyproheptadine |